Pharma News

On November 21, 2024, Bayer announced that a Supplemental New Drug Application (sNDA) for its product darotamine (trade name: Nubeqa) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive pr

On November 17, 2024, the Financial Times reported that Danish pharmaceutical giant Novo Nordisk plans to publish final clinical trial data for its new generation weight loss drug CagriSema next month. According to Novo Nordisk, the results of the trial w

On November 19, 2024, Beigene announced that it had reached a settlement agreement with pharmaceutical company MSN on a patent dispute related to Zeebutinib. Under the agreement, the State of Beigene grants MSN the rights to sell generic versions of Zeebu

On November 20, 2024, Pfizer announced that, effective January 1, 2025, Dr. Chris Boshoff will serve as the company's Chief Scientific Officer and President of Research and Development.

On November 7, 2024, researchers from Osaka University published a research paper entitled "Transplantation using Induced pluripotent stem cell-derived corneal epithelial cell tablets: a single-arm, open-label, first-in-human intervention study in Japan"

On November 18, 2024, Wantai Bio-issued an official announcement announcing that the clinical trial of its nine-valent HPV vaccine for the indication of the male population has been approved by the State Drug Administration.

Eli Lilly and Company recently announced positive results in a Phase 2 clinical trial for muvalaplin, its once-daily oral lipoprotein (a) -- Lp (a) inhibitor. The study results showed that the trial met its primary endpoint, and muvalaplin was able to sig

According to an update released on November 18, 2024, Gilead plans to relieve 104 employees at its Foster City headquarters on March 14, 2025.

At the World Congress on Lung Cancer in September 2024, Kangfang Biotics released Evoxil monotherapy (PD-1/VEGF bispecial antibody) and Merck Pabolizumab monotherapy in the first-line treatment of PD-L1 expression positive (PD-L1 Key data from a registere

The case is SEC v. CR Intrinsic Investors LLC et al, U.S. District Court, Southern District of New York, No. 12-08466.

At a medical meeting on Monday, Eli Lilly presented data from a study showing that its experimental drug muvalaplin significantly reduced levels of inherited high cholesterol in a mid-stage trial.

Johnson & Johnson announced on Monday that in a late-stage clinical trial, the company's oral drug for the treatment of specific skin conditions has achieved its primary goal of significantly improving the condition of the skin to a point where it is clea

The Codex Alimentarius Commission (CAC) published CL 2024/86-CAC on November 13, 2024, to revise a number of special dietary standards and to seek public comment, with a deadline of November 20, 2024. The main contents of the revision are as follows:

On November 15, 2024, the European Food Safety Authority (EFSA) published a public consultation document, number PC-1204, which seeks to authorise the use of esterified propoxylated glycerol (EPG) as a novel food, with a deadline of December 6, 2024. The

Recently, according to the latest information released on the official website of the National Medical Products Administration (NMPA), four generic drugs submitted by Jiangsu Huayang Pharmaceutical Co., Ltd. have been approved and identified as equivalent

On November 13, 2024, Primis Biotechnology Co., LTD. (hereinafter referred to as "Primis"), founded by former Cinda R&D senior executive Liu Xiaolin, announced the signing of an equity acquisition agreement with German pharmaceutical company BioNTech.

The Senate has yet to vote on the nomination, and it remains to be seen whether Kennedy will succeed.

On November 6, 2024, the results of the high-profile US election were finally announced, and the return of the Trump era indicates what kind of changes the US health care policy, as one of the core issues of voter concern, will undergo in the future.

On November 14, Merck announced that it has reached an agreement with Lixin Pharmaceutical to obtain exclusive global development, production and commercialization rights for Lixin Pharmaceutical's new PD-1/VEGF bispecpecic antibody LM-299.

Japanese pharmaceutical company Eisai has significantly lowered its sales forecast for its Alzheimer's treatment Leqembi, predicting a 25% reduction in sales in fiscal year 2024.